On Friday, Evercore ISI initiated coverage on Edgewise Therapeutics (NASDAQ:EWTX) shares, a biopharmaceutical company, with an Outperform rating and a price target of ...

Edgewise Therapeutics (NASDAQ:EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) experienced a notable 21% increase in premarket trading today following the announcement of successful results from its Phase 2 CANYON trial. The ...

Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy. The stock rose 5.4% to $29.11 ...

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of ...